Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2936 • 2014 ACR/ARHP Annual Meeting
Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases, and How Does These Risks Compare to Those in Rheumatoid Arthritis?
Johan Askling¹, Lennart Jacobsson² and Jonas Eriksson¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²sahlrenska academy, gothenburg, Sweden
Background/Purpose Patients with RA are at increased risk of cardiovascular (CV) diseases, including acute coronary syndromes (ACS), deep venous thromboembolism (DVT) and pulmonary embolism (PE),…
Abstract Number: 2024 • 2014 ACR/ARHP Annual Meeting
Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study
Michel De Bandt¹, Rishika Banydeen², Lauren Brunier³, Katleen Polomat⁴, Veronique Dehlinger⁵, Serge Arfi⁴, Christophe Deligny⁴, Benedicte Garnery⁶, Helene Cormier⁷, Fabienne Dubreuil⁸, Patrick Numeric⁹, Danielle Dufrenot¹⁰, Sabine Molcard⁷, Loic Brithmer⁷, Olivier Fuhrer⁷, Lucien Louis-Joseph¹¹, Sylvie Merle² and Georges Jean-Baptiste⁵, ¹CHUM de Martinique, Unit of rheumatology, Fort de France, France, ²Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of epidemiology and biostatistics, Fort de FRance, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ⁴CHUM de Martinique,, unit of internal medicine, Fort de France, France, ⁵CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁶Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of internal medicine, Fort de France, France, ⁷Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de France, France, ⁸Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of rheumatology, Fort de FRance, France, ⁹route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ¹⁰Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fot de France, France, ¹¹Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de FRance, France
Background/Purpose Rheumatoid arthritis (RA) is a disabling chronic disease, regarded as the most frequent inflammatory rheumatism in adults, with a prevalence estimated between 0.3 and…
Abstract Number: 1385 • 2014 ACR/ARHP Annual Meeting
What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study
Agnès Danré¹, Bruno Fautrel², Toni Alfaiate³, Thao Pham⁴, Jacques Morel⁵, Emmanuelle Dernis Labous⁶, Philippe Gaudin⁷, Olivier Brocq⁸, Elisabeth Solau-Gervais⁹, Jean-Marie Berthelot¹⁰, Jean Charles Balblanc¹¹, Xavier Mariette¹², Florence Tubach¹³ and Laure Gossec¹⁴, ¹Rheumatology, La Pitié Salpêtrière, Paris, France, ²Rheumatology, Pitie Salpetriere Hospital, Paris, France, ³department of epidemiology, biostatistics and clinical research, APHP, Hospital Bichat, Paris, France, ⁴Rheumatology, Sainte Marguerite Hospital, Marseille, France, ⁵Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁶Rhumatologie, Ch Du Mans, Le Mans, France, ⁷Rhumatologie, Hopital Sud Grenoble, Echirolles, France, ⁸Rheumatology, Hospital of Princesse Grâce de Monaco, Monaco, France, ⁹Rheumatology, University Hospital of Poitiers, Poitiers, France, ¹⁰Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, ¹¹Rhumatologie, Ch de Belfort, Belfort Cedex, France, ¹²Rheumatology, University Hospital, Le Kremlin Bicetre, Paris, France, ¹³INSERM, Universite Paris Diderot, Paris, France, ¹⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose Flares in rheumatoid arthritis (RA) are a patient-perceived increase of disease activity which might be particularly important to assess in the context of treatment…
Abstract Number: 459 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis
J. Kremer¹, A.J. Kivitz², J.a. Simon Campos³, E.L. Nasonov⁴, H. Tony⁵, B. Vlahos⁶, C. Hammond⁶, J. Bukowski⁶, H. Li⁶, S. Schulman⁶, S. Raber⁷, A. Zuckerman⁸ and J. Isaacs⁹, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Hospital CEM/BIOCEM, Merida, Mexico, ⁴Nasonova State Institute of Rheumatology, Moscow, Russia, ⁵University Hospital Würzburg, Würzburg, Germany, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, San Diego, CA, ⁸Pfizer Inc, Groton, CT, ⁹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: In the clinical development program of the oral Janus kinase inhibitor tofacitinib for the treatment of rheumatoid arthritis (RA), small mean increases in serum…
Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Priyanka Vashisht¹, Jessica M. Dorschner², Mark A. Jensen³, Beverly Chrabot⁴, Theresa Wampler Muskardin⁵, Marlena Kern⁶, Tetrad Investigators⁷, ABCoN Consortium⁸, S. Louis Bridges Jr.^9,10, P.K. Gregersen¹¹ and Timothy B. Niewold², ¹Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁶North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, ⁷AL, ⁸NY, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…
Abstract Number: 1962 • 2014 ACR/ARHP Annual Meeting
Inflammatory Properties of Inhibitor of DNA Binding 1 As a Unique Fibroblast Derived Nuclear Protein
Gautam Edhayan¹, Christine M. Ha¹, Ray A. Ohara¹, Takeo Isozaki¹, M. Asif Amin¹, Ali Arbab², Pei-Suen Tsou³, Phillip L. Campbell⁴, Elena Schiopu³, Dinesh Khanna³, Rachel Morgan¹, Sean C. Friday¹, David A. Fox¹ and Jeffrey Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³University of Michigan Scleroderma Program, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding 1 (Id1) is a nuclear protein containing a basic helix-loop-helix (bHLH) domain that regulates cell growth by selective binding and…
Abstract Number: 1368 • 2014 ACR/ARHP Annual Meeting
Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis?
Peter Cheung¹, Karine Mari², Valerie Devauchelle³, Jacques Bentin⁴, Sandrine Jousse-Joulin⁵, Maria-Antonietta d'Agostino⁶, Gérard Chales⁷, Isabelle Chary-Valckenaere⁸, Fabien Etchepare⁹, Philippe Gaudin¹⁰, Xavier Mariette¹¹, Alain Saraux¹² and Maxime Dougados¹³, ¹Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²RCT, Lyon, France, ³Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ⁴Rheumatology, CHU-Brugmann, Brussels, Belgium, ⁵Rheumatology, CHU Brest, Brest, France, ⁶Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁷Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁸Rheumatology, Nancy University Hospital, Nancy, France, ⁹AP-HP, La Pitié-Salpétrière Hospital, Rheumatology Department, Paris-VI University, Paris, France, ¹⁰Rhumatologie, Hopital Sud Grenoble, Echirolles, France, ¹¹Paris-Sud University, Paris, France, ¹²Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France, ¹³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Longitudinal studies indicate that synovitis can predict subsequent structural damage in rheumatoid arthritis (RA) but the clinical relevance of tenderness is unclear. The aim…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 2819 • 2014 ACR/ARHP Annual Meeting
The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion
Beatrix Bartok, Division of Rheumatology, allergy and immunology, University of California, San Diego, La Jolla, CA
Background/Purpose: Fibroblast like synoviocytes (FLS) in RA possesses unique transformed phenotype, such as cartilage invasion that is maintained independent of cytokines and other inflammatory cells.…
Abstract Number: 1837 • 2014 ACR/ARHP Annual Meeting
First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis
Louise Mercer¹, Xavier Mariette², William Dixon¹, Eva Baecklund³, Karin Hellgren⁴, Lene Dreyer⁵, Merete Lund Hetland⁶, Lene Mellemkjær⁷, Kimme Hyrich⁸, Anja Strangfeld⁹, Angela Zink¹⁰, Helena Canhao¹¹, Fernando Martins¹², Victoria Hernández¹³, Florence Tubach¹⁴, Jacques-Eric Gottenberg¹⁵, Jacques Morel¹⁶, Jakub Zavada¹⁷, Piet van Riel¹⁸, Axel Finckh¹⁹, Florenzo Iannone²⁰, Johan Askling²¹ and Joachim Listing²², ¹The University of Manchester, Manchester, United Kingdom, ²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ³Uppsala University, Uppsala, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Copenhagen University Hospital at Gentofte, Gentofte, Denmark, ⁶On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ⁷Virus, Lifestyle and Genes, The Danish Cancer Society, Copenhagen, Denmark, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ¹⁰German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ¹¹Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ¹²Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, ¹³BIOBADASER Registry, Madrid, Spain, ¹⁴INSERM, Universite Paris Diderot, Paris, France, ¹⁵Department of rheumatology CHU, Strasbourg, France, ¹⁶Universite´ Montpellier, Montpellier, France, ¹⁷Charles University, Prague, Czech Republic, ¹⁸Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²⁰Reumatologia Universita e Policlinico di Bari, Bari, Italy, ²¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²²German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 2-3 fold increased risk of both Hodgkin and non-Hodgkin lymphoma (HL; NHL). The risk of lymphoma, in…
Abstract Number: 1210 • 2014 ACR/ARHP Annual Meeting
The Role of the Transcription Factor cAMP Responsive Element Binding Protein 1 in Lipopolysaccharide-Induced Tolerance
Kerstin Klein¹, Renate E. Gay², Christoph Kolling³, Lih-Ling Lin⁴, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ³Schulthess Clinic, Zurich, Switzerland, ⁴Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA
Background/Purpose In macrophages, repeated stimulation of Toll-like receptor (TLR) 4 leads to adaptation of signaling pathways and epigenetic modifications resulting in a tolerant state of…
Abstract Number: 444 • 2014 ACR/ARHP Annual Meeting
Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis
Ray A. Ohara¹, Gautam Edhayan¹, Christine M. Ha¹, M. Asif Amin¹, Ali S. Arbab², Phillip L. Campbell³, David A. Fox¹ and Jeffrey H. Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification mediated by peptidyl arginine deiminase (PAD) enzyme in which arginine is converted to citrulline. Inhibitor of DNA binding 1…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Stephen Lindsey¹, Brandi Oufnac² and Holly Walker², ¹Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ²Rheumatology, Ochsner Health Systems, Baton Rouge, LA
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].